{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.2","upperLimit":"30.9","value":"19.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"}],"units":"Participants"}],"description":"ORR was defined as the percentage of the participants who achieved a confirmed partial response or better (i.e., PR, VGPR, CR, or sCR) based on the IRC's response outcome assessments, according to the IMWG response criteria. PR: \\>=50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \\>=90% or \\<200 mg per 24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \\<100 mg per 24 hours; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\<=5% plasma cells in bone marrow; or sCR: CR as defined as Normal FLC ratio+ Absence of clonal cells in bone marrow biopsy by immunohistochemistry.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in the VD arm who had IRC-confirmed PD and were able to tolerate continued bortezomib treatment had crossed over to receive fixed oral dose of 100 mg selinexor tablets (5 tablets of 20 mg each) QW on Days 1, 8, 15, 22, and 29 of each 35-day cycle, along with SC injection of 1.3 mg/m\\^2 bortezomib QW on Days 1, 8, 15, and 22 of each 35-day cycle, and an oral dose of 20 mg of dexamethasone BIW on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle until PD confirmed by the IRC, investigator or participant decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that could not be managed by supportive care, withdrawal of consent, death, or sponsor decision to terminate the study.","id":"OG000","title":"SVdX Arm: Selinexor + Bortezomib + Dexamethasone"}],"paramType":"NUMBER","populationDescription":"The SVdX population consisted of a subset of participants in the Vd arm of the safety population who crossed over from the Vd arm to SVdX treatment after IRC confirmation of PD on Vd and had received at least 1 dose of selinexor. Here, \"Overall number of participants analyzed\" signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From date of first SVdX treatment until disease progression or initiating a new MM treatment (up to 33 months)","title":"SVdX Arm: Overall Response Rate (ORR1) as Assessed by IRC During SVdX Treatment","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}